The Life Sciences team advised Quench Bio through the completion of a $50 million Series A financing led by RA Capital Management, with participation from new investor Abbvie Ventures. Atlas Venture and Arix Bioscience plc who co-founded and seeded the company, also participated in the Series A.
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases. Quench's lead compounds target and inhibit the pore-forming protein Gasdermin D, a central player in both pyroptosis and NETosis pathways that mediates the release of inflammatory cytokines, alarmins, DNA and NETs. Quench Bio launched in January 2020 with $50 million from leading life science investors including Atlas Venture, Arix Bioscience, RA Capital and AbbVie Ventures.